61 results about "Neovascularization" patented technology

The invention relates to morin nanoparticles, pH responsive hydrogel and application of the morin nanoparticles and the pH responsive hydrogel. The morin-loaded nanoparticles provided by the invention can be rapidly degraded in an alkaline environment, have certain stability in an acidic environment, have the capability of releasing morin in response to pH, and can realize accurate regulation and control of morin release according to the change of environmental pH. According to the invention, hyaluronic acid is further subjected to methacrylation treatment, such that MeHA is obtained. The characteristic that MeHA is easier to degrade in an acid environment is utilized, and MeHA is used as hydrogel to load CFMNPs and can be effectively used for treating wounds caused by burns and frostbite. Furthermore, the pH responsive double-layer hydrogel based on pigment nanoparticles-basic fibroblast growth factors can realize sequential release of the effective components according to the change of the pH value of the burn or frostbite wound. The composition can effectively inhibit inflammation, resist oxidative stress, promote proliferation and migration of endothelial cells, promote neovascularization and finally accelerate wound healing.

Compositions and methods of using nintedanib for treating indications with abnormal neovascularization in the front part of the eye are disclosed.

The invention belongs to the field of new application of medicines, and particularly relates to application of triptolide in preparation of medicines for treating diabetic vascular obstruction complications. Diabetes vascular obstruction is a common serious complication of diabetes and can cause various tissue injuries such as cardiovascular diseases, nephropathy and retinopathy. Experiments prove that the triptolide can remarkably improve the problems of blood vessel blockage, blood flow slowing, abnormal neovascularization and the like caused in a high-glucose environment, and meanwhile, the expression of blood glucose related indexes (such as Glucose and HbA1c) and inflammatory factors (such as TNF-alpha and IL-1beta) is reduced. In addition, triptolide can also protect pancreas from high glucose damage and improve functions of pancreatic beta cells. According to the invention, the clinical application range of the triptolide is expanded, and a new candidate substance is provided for drug treatment of diabetic vascular complications.

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina / vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

The application discloses a VEGF / TIE-2 double-targeting polypeptide and application thereof in preparation of an antitumor drug, and relates to the technical field of biological medicine.The VEGF / TIE-2 double-targeting polypeptide (named as RTP) provided by the application is composed of an amino acid sequence capable of target-recognizing VEGF and TIE-2, an amino acid sequence capable of self-assembling to form a beta-sheet nanofiber, an amino acid sequence capable of target-recognizing carbonic anhydrase IX and an enzyme-reactive amino acid sequence capable of being specifically cut by MMP-2.RTP can occur conformational change and self-assemble in tumor cells to form stable water-insoluble nanofibers, and can strongly inhibit tumor neovascularization and metastasis through the VEGF and TIE-2 double-signal pathways and inhibit the progress of the tumor.

The application discloses a choroid neovascularization image segmentation method based on a hybrid convolutional network, first, collecting fundus OCT scan images and labeling, and forming a data set by using the labeled images; a deep space-time separation hybrid convolutional neural network fusing an attention mechanism is constructed, two-dimensional feature extraction is carried out by using two-dimensional convolution, then the two-dimensional feature extraction is extended to three-dimensional, and then three-dimensional attention deep space-time separation convolution is carried out, and the two-dimensional feature and the three-dimensional feature are aligned and fused; then the hybrid neural network model constructed is trained by using the data set; finally, the trained hybrid neural network model is used to segment choroid neovascularization from the fundus OCT scan images, and a segmentation result is obtained. Through the space-time attention mechanism, local features of the choroid neovascularization image are better extracted, and by using the deep space-time separation convolution, a dimension reduction operation is carried out on the input feature map, so that the calculation parameters can be effectively reduced, thereby reducing the network calculation amount, and the channel attention can be more effectively calculated.

The invention discloses an antibacterial hydroxyapatite fiber-gelatin composite scaffold as well as a preparation method and application thereof, the composite scaffold has the structural characteristics of regular spherical macropores and communicating pores, and the interior of the composite scaffold is formed by mutually interwoven antibacterial hydroxyapatite fiber-gelatin composite fibers; the preparation method comprises the following steps: injecting antibacterial hydroxyapatite fiber / gelatin turbid liquid into a paraffin ball template under negative pressure, and carrying out thermal cooling phase separation and a paraffin ball template leaching technology. The composite scaffold integrates multiple functions of active antibiosis, osteogenic differentiation promotion, neovascularization and bone tissue ingrowth and the like, and has huge application potential in the field of promotion of rapid repair and regeneration of infectious bone defects.

Provided herein are novel reprogrammed smooth muscle cells (rSMCs) and methods of making and using the cells for the treatment of ischemia. The rSMCs are produced by culturing a fibroblast with an all-trans-retinoic acid (ATRA) under conditions that produce the rSMC from the fibroblast, wherein the fibroblasts are genetically modified to overexpress myocardin. The rSMCs offer advantages over currently available regenerative vascular therapies by promoting vascular perfusion in a recipient subject. In particular, the rSMCs can increase neovascularization of both small and large vessels.

The invention provides a process for preparing a Biochanin A (BCA)-loaded hydroxypropyl methyl cellulose (HPMC) hydrogel aimed at promoting wound healing in diabetic patients. The hydrogel is prepared by dispersing HPMC in distilled water, followed by dissolving BCA into the mixture with continuous stirring, then storing under refrigeration. The therapeutic potential of Biochanin A (BCA) in promoting wound healing, is evaluated in rats induced with diabetes. The results showed that the BCA-loaded hydrogel accelerates diabetic wound repair by boosting antioxidant defenses via upregulating Nrf2 and related enzymes, suppressing inflammatory markers such as IL-1β, IL-6, TNF-α, COX-2, and TLR4, and stimulating angiogenesis through increased expression of TGF-β1, VEGF-A, and PDGFR. It promotes faster wound contraction, re-epithelialization, collagen deposition, granulation tissue formation, and neovascularization, potentially reducing the risk of complications like limb amputation. The invention offers a promising therapeutic approach for treating chronic diabetic wounds with improved healing outcomes.

This invention provides a method for treating ocular indications involving abnormal neovascularization. [Solution] The present invention provides a method comprising the step of administering an effective amount of nintedanib or a pharmaceutically acceptable salt thereof in the form of a topical eye drop or implant to the eye of a subject.

The utility model relates to a kind of nanostructure of laser surface treatment aggregate, wherein the surface of the aggregate is titanium metal, and at least one microchannel with titanium dioxide (TiO2) after cooling is formed by laser melting and sputtering to form molten titanium, at least one microchannel includes: at least one micropore, at least one guide channel, and at least one nano-wall formed at least one nano-bulge layer and at least one nano-wall. The following bone healing and antibacterial index effects and purposes are achieved: A. accelerate bone healing related protein deposition, B. accelerate bone cell attachment, C. induce neovascularization, D. accelerate early calcification and bone mineralization, E. improve nutrient exchange, F. stabilize surface bone structure, and G. resist plaque formation.

The present invention belongs to the field of tumor immunotherapy, and relates to a humanized anti-VEGF antibody Fab fragment. The present invention discloses nucleic acid sequences (including heavy / light chain variable regions) encoding said antibody fragment, and vectors, pharmaceutical compositions and kits containing said nucleic acid sequences. The anti-VEGF antibody Fab fragments disclosed in the present invention can specifically bind to VEGF with high affinity and block the binding of VEGF to the receptor VEGFR2, and also neutralize the proliferative effect of VEGF on HUVEC cells. Compared to the full-length antibody, antibodies in the form of Fab fragments have stronger penetrability and less toxic in terms of gastrointestinal perforation, hypertension and hemorrhage and do not stimulate the complement cascade reaction, thus reducing the risk of endophthalmitis and autoimmune inflammatory reactions. Thus it could be used in clinical treatment of ocular diseases characterized by choroidal neovascularization, including but not limited to age-related macular degeneration (AMD), diabetic macular edema (DME), retinal edema, degenerative myopia, choroidal neovascularization (CNV).

A film for integrating with tissue and promoting at least one of endothelial cell adhesion, migration, proliferation, ingrowth, infiltration, angiogenesis, sprouting angiogenesis, neovascularization, and vascularization includes a plurality of fibers arranged in an overlapping configuration to form a porous, thin film with an average pore size of at least 0.01 μm2 and less than 60 μm2. The plurality of fibers has an average diameter of at least 10 nm and less than 1,000 nm. Each of the plurality of fibers have an aspect ratio of length to width of at least 10, and each of the plurality of fibers is a biocompatible material.

The present invention relates to sitagliptin or a pharmaceutically or veterinary acceptable salt thereof for use in the local eye treatment of neovascular retinal diseases. The invention also encompasses pharmaceutical or veterinary compositions for use in the local treatment of these diseases.

The invention belongs to the technical field of biological pharmacy, and provides an application of a serum LECT2 level in cardiac remodeling and coronary angiogenesis prediction after myocardial infarction, and the application is that the serum LECT2 level is used as a marker to be applied to cardiac remodeling and coronary angiogenesis prediction after myocardial infarction. By establishing a myocardial infarction animal model and comparing serum LECT2 levels in blood of healthy people, myocardial infarction patients and coronary artery occlusion patients, the prognosis effect of the serum LECT2 expression level in myocardial infarction and coronary artery occlusion diseases is evaluated. Results show that the serum LECT2 level can be used as an effective index for predicting coronary angiogenesis after myocardial infarction and prognosis of patients, and clinicians can adjust a treatment scheme in time and optimize patient management by detecting the serum LECT2 level.

This invention relates to a self-assembling polypeptide for regulating the permeability of retinal pigment epithelium (RPE), its preparation method, and its applications. The self-assembling polypeptide comprises an integrin receptor-targeting peptide, a self-assembling polypeptide, and a hydrophobic molecule sequentially linked. The self-assembling polypeptide designed in this invention can self-assemble into nanoparticles and specifically target RPE cells. After interacting with receptors on the cell membrane, the nanoparticles transform into nanofibers, achieving rapid targeted enrichment of RPE tissue. Furthermore, by regulating the permeability of RPE tissue, it can enhance the transcellular drug transport capacity, providing a new clinical application strategy for the treatment of macular neovascularization, especially polypoid choroidal vascular lesions.

The invention discloses a preparation method of an IL11 siRNA (at) EVs multi-stage stent and application of the IL11 siRNA (at) EVs multi-stage stent in preparation of kidney defect repair products, and belongs to the technical field of medicine products. By combining ultracentrifugation with an electroporation technology, IL11 siRNA is efficiently loaded in the stem cell-derived extracellular vesicles, and the encapsulation efficiency is high. GelMA / HAMA is used as biological ink, Alg fibers are added, elution is performed after 3D printing, and the macroscopic and microchannel communicated multistage channel network stent is constructed. The stent simulates a kidney structure, the mechanical property is matched with that of a natural kidney, and compared with a traditional hydrogel stent, cell infiltration and neovascularization are effectively guided. The channel structure and mechanical properties of the multi-stage stent prepared by simple physical mixing and DLP 3D printing are not affected, and IL11 siRNA (at) EVs are uniformly distributed in the stent and can be continuously released in the damaged kidney for more than 14 days. Compared with systemic administration, the stent has the advantages that renal injury and fibrosis after partial renal resection can be remarkably relieved, endogenous repair is accelerated, and an ideal scheme is provided for repair after partial renal resection.

The application discloses application of harman alkaline in preparation of a medicine for treating and / or preventing myocardial infarction; the application firstly finds that the harman alkaline can be used for treating and / or preventing myocardial infarction. Meanwhile, the harman alkaline can significantly reduce a myocardial infarction area, improve heart function, and promote blood vessel neogenesis in an infarction edge area; and the harman alkaline can also up-regulate protein expression of CD31. In a cell experiment, the harman alkaline can promote HUVEC cell migration and proliferation after H2O2 injury. The application discloses the anti-myocardial infarction effect of the harman alkaline, provides a new medicine for myocardial infarction treatment, and has important clinical application value.

Systems and methods for providing artificial implants that promote neovascularization using an implant body enclosing biomaterial and a length of an arteriovenous (AV) bundle. The AV bundle can be configured to have closed ends that reside in or outside the internal chamber of the implant body so as to not form a blood flow path therebetween. The biomaterial can include decellularized human pancreatic extracellular material in the internal chamber. The biomaterial can be pre-formed or pre-assembled or injected into the internal chamber of the implant body or the biomaterial or inserted onsite during or prior to a surgical procedure associated with implantation of the device.

The present invention relates to a composition for inhibiting angiogenesis containing yohimbine, and more specifically, to a pharmaceutical preparation and a functional food containing a composition capable of exhibiting preventive, improving, and therapeutic effects on angiogenesis-related diseases such as hemangioma, vascular adhesion, neovascular glaucoma, diabetic retinopathy, macular degeneration, corneal disease caused by neovascularization, or telangiectasia by containing yohimbine capable of inhibiting PDGF-induced vascular smooth muscle cell proliferation and migration through the factor FOXO3a.

The present invention relates to a therapeutic freeze-dried or frozen cell in which the cell surface is treated with a polyphenol, a method for preparing the same, and a pharmaceutical composition comprising the same. The polyphenol-treated lyocell for treatment of the present invention can act as a biological repository for controlling the release of a variety of physiologically active molecules including endogenous substances and therapeutic drugs in the cell. Furthermore, the polyphenol-treated frozen cells for treatment contain an intracellular physiologically active substance increased and / or concentrated, for example, a growth factor, an immunomodulatory factor or the like, and can be used as a composition for preventing or treating ischemic diseases by an angiogenesis promoting effect. The composition can be used as a composition for preventing, ameliorating or treating inflammatory diseases by the improved immunomodulatory function. Meanwhile, when the therapeutic cell (lyocell) is used as an appropriate drug delivery technique before freezing (drying), it is expected to construct a cell drug system that can be simply and efficiently used.

The present invention provides a nanostructure of a laser surface-treated bone material. [Solution] The surface of the bone material is titanium metal 3, and molten titanium metal is formed by laser sputtering. After cooling, it has at least one microchannel 10 made of titanium dioxide (TiO2). The nanostructure of the bone material includes at least one micropore 12, at least one guide channel 16, at least one nanoprotrusion particle layer 111 formed by at least one nanowall 11, and at least one nanowall. The effects and purposes of improving bone healing and antibacterial indicators are achieved: A. accelerating the deposition of bone healing-related proteins; B. accelerating the attachment of bone cells; C. inducing neovascularization; D. accelerating early calcification and bone mineralization; E. improving the exchange of nutrients; F. stabilizing the surface bone structure; and G. inhibiting plaque formation.

The present invention relates generally to shape memory polymer devices that are porous. The porosity of the device may generate advantageous neovascularization, decrease inflammation, and decrease fibrosis. The device may include a surface having a pore size of 400 μm-1200 μm and a pore spacing of about 100 μm to about 750 μm.

Provided is a nanoparticle or a pharmaceutical composition including the same for treating or remitting a neovascularization or an angiogenesis in eye segments, and the nanoparticle includes a hyaluronic acid and a therapeutic peptide. Also provided is a method for inhibiting formation or growth of blood vessels by administration of the nanoparticle or the pharmaceutical composition of the present disclosure to a subject in need thereof.

Provided are an artemisinin derivative and a preparation method and use thereof. A structural formula of the artemisinin derivative is shown in Formula I. The compound has suitable solubility and is relatively stable under storage conditions. Pharmacokinetic experiments on the compound have shown that artemisinin is detectable in ocular tissues and is present in cornea, conjunctiva, and aqueous humor at a relatively high drug concentration. The compound is therefore an excellent precursor to artemisinin. The compound shown in Formula I exhibits remarkable absorbability, and the drug concentration in the ocular tissues indicates that the compound is well absorbed. The compound exhibits significantly better inhibitory effects on neovascularization in burn models than artemisinin, and can be prepared into liquid formulations such as eye drops, injection, etc., for treatment of ocular tissue diseases.

The invention belongs to the technical field of biomedical materials, and particularly relates to a COFs (covalent organic frameworks)-based conductive hydrogel material and application of the COFs-based conductive hydrogel material in electric-assisted promotion of healing of diabetic wounds. The preparation method comprises the following steps: forming a covalent organic framework, enabling the covalent organic framework to grow on reduced graphene oxide in situ to form a nano material with a highly-ordered porous crystal structure, loading the nano material to form polyacrylamide hydrogel, and preparing the flexible hydrogel material into the multifunctional patch through a flexible electrode system. Through a triple synergistic mechanism of photo-thermal sterilization, electrochemical ROS cleaning and cell / immune regulation, the microenvironment obstacle of diabetes wound healing is broken through, ordered collagenous fiber deposition and angiogenesis are promoted, and tissue mechanical strength and blood supply reconstruction are improved. Scar formation is reduced, and the skin barrier function integrity is recovered. And through the flexible wearable characteristic, the problems of portability and comfort pain points of clinical treatment are solved, and intelligent wireless control provides technical support for precise medical treatment.

The present specification relates to compounds for inhibiting neovascularization factors and use thereof. Furthermore, the present specification relates to methods for treating neovascularization diseases using the compounds.

Described herein are compositions for modulating transgene expression of one or more therapeutic agents. In some aspects, an engineered polynucleotide comprises one or more expression cassettes, the one or more expression cassettes encoding a first angiogenesis inhibitor and a second angiogenesis inhibitor. Also described herein are methods of using the compositions described herein for modulating transgene expression and for treating diseases or conditions, in particular therapeutic agents for treating ocular diseases or inhibiting neovascularization.

The invention relates to the technical field of biological medicine, in particular to ureido indolone compounds and a preparation method and application thereof. Compared with the prior art, the ureido indolone compound provided by the invention has the advantages that the activity of VEGFR, PDGFR and / or FGFR can be effectively inhibited, signal transduction of VEGF, PDGF and / or FGF is blocked, and systemic neovascularization (abnormal vascular hyperplasia) related diseases are treated.